| [1] | Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN (2002) Acne therapy: A methodologic review. J Am Acad Dermatol 47: 231–240.
|
| [2] | Jewett S, Ryan T (1985) Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med 20: 425–429.
|
| [3] | Cunliffe WJ (1986) Acne and unemployment. Br J Dermatol 115: 386.
|
| [4] | Cotterill JA, Cunliffe WJ (1997) Suicide in dermatological patients. Br J Dermatol 137: 246–250.
|
| [5] | Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, et al. (1984) Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 10: 490–496.
|
| [6] | Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, et al. (1985) Retinoic acid embryopathy. N Engl J Med 313(14): 837–841.
|
| [7] | Mitchell AA, Van Bennekom CM, Louik C (1995) A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 333: 101–106.
|
| [8] | Lindstrom J (2004) Isotretinoin: Background and regulatory history. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/s？lides/4017s1.htm. Accessed 13 October 2006.
|
| [9] | Wysowski DK, Pitts M, Beitz J (2001) An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 45: 515–519.
|
| [10] | Stern RS (2000) Medication and medical service utilization for acne 1995–1998. J Am Acad Dermatol 43: 1042–1048.
|
| [11] | Chen K, White TJ, Juzba M, Chang E (2002) Oral isotretinoin: An analysis of its utilization in a managed care organization. J Manag Care Pharm 8: 272–277.
|
| [12] | Wysowski DK, Swann J, Vega A (2002) Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol 46: 505–509.
|
| [13] | Food and Drug Administration (2006) iPLEDGE update. Available: http://www.fda.gov/cder/drug/infopage/ac？cutane/iPLEDGEupdate200603.htm. Accessed 18 October 2006.
|
| [14] | McGuire WJ (1984) Public communication as a strategy for inducing health-promoting behavioral change. Prev Med 13: 299–319.
|
| [15] | Synder LB, Hamilton MA, Mithchell EW, Kiwanuka-Tondo J, Fleming-Milici F, et al. (2004) A meta-analysis of the effect of mediated health communication campaigns on behavior change in the United States. J Health Commun 9(Suppl 1): 71–96.
|
| [16] | Bandura A (1986) Social foundations of thought and action: A social cognitive theory. Englewood Cliffs (NJ): Prentice-Hall. 544 p.
|
| [17] | Glanz K, Rimer BK, Lewis FM, editors. (2002) Health behavior and health education: Theory, research and practice. 3rd edition. San Francisco: Jossey-Bass. 624 p. editors.
|
| [18] | Food and Drug Administration (1983) Dermatologic Drugs Advisory Committee Transcript: October 21, 1983. Available: http://www.fda.gov/ohrms/dockets/ac/accu？tane.htm. Accessed 18 October 2006.
|
| [19] | Food and Drug Administration (1988) Dermatologic Drugs Advisory Committee Transcript: April 26, 1988. Available: http://www.fda.gov/ohrms/dockets/ac/accu？tane.htm. Accessed 18 October 2006.
|
| [20] | Perlman SE, Leach EE, Dominguez L, Ruszkowski AM, Rudy SJ (2001) “Be smart, be safe, be sure”. The revised Pregnancy Prevention Program for women on isotretinoin. J Reprod Med 46(Suppl 2): 179–185.
|
| [21] | Honein MA, Paulozzi LJ, Erickson JD (2001) Continued occurrence of Accutane-exposed pregnancies. Teratology 64: 142–147.
|
| [22] | Brinker A, Kornegay C, Nourjah P (2005) Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 141: 563–569.
|
| [23] | Shiff SA (2004) Overview of SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/s？lides/4017s1.htm. Accessed 18 October 2006.
|
| [24] | Darves B (2006 March 9) Dermatologists frustrated with problematic iPledge program. Medscape Medical News. Available: http://www.medscape.com/viewarticle/5256？64. Accessed 18 October 2006.
|
| [25] | Harris G (2006 February 11) System said to fail to steer women from acne drug. The New York Times. Available: http://www.nytimes.com/2006/02/11/nation？al/11inhibit.html. Accessed 18 October 2006.
|
| [26] | Huber MH (2004) Review of Data from SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/s？lides/4017s1.htm. Accessed 18 October 2006.
|
| [27] | Brown SS, Eisenberg L, editors. (1995) The best intentions: Unintended pregnancy and the well-being of children and families. Washington (D. C.): National Academy Press. 392 p. editors.
|
| [28] | Honein MA, Moore CA, Erickson JD (2004) Can we ensure the safe use of known human teratogens? Drug Saf 27: 1069–1080.
|
| [29] | Andreasen AR (1995) Marketing social change: Changing behavior to promote health, social development, and the environment. San Francisco: Jossey-Bass. 368 p.
|
| [30] | Doak CC, Doak LG, Root JH (1996) Teaching patients with low literacy skills. Philadelphia: Lippincott.
|
| [31] | Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, et al. (2004) A catalog of dermatology utilities: A measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9: 160–168.
|
| [32] | Rohrback JM, Fleischer AB Jr, Krowchuk DP, Feldman SR (2004) Depression is not common in isotretinoin-treated acne patients. J Dermatolog Treat 15: 252.
|
| [33] | Jick SS, Kremers HM, Vasilakis-Scaramozza C (2000) Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 136: 1231–1236.
|
| [34] | Fleischer AB Jr, Simpson JK, McMichael A, Feldman SR (2003) Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States? J Am Acad Dermatol 49: 662–666.
|
| [35] | Cheetham TC, Wagner RA, Chiu G, Day JM, Yoshinaga MA, et al. (2006) A risk management program aimed at preventing fetal exposure to isotretinoin: Retrospective cohort study. J Am Acad Dermatol 55: 442–448.
|
| [36] | Thevarajah S, Balkrishnan R, Camacho FT, Feldman SR, Fleischer AB Jr (2005) Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment. J Dermatolog Treat 16: 224–228.
|
| [37] | Jordan AY, Parks L, Chen SC, Higgins K, Fleischer AB, et al. (2005) Does the teratogenicity of isotretinoin outweigh its benefits? J Dermatolog Treat 16: 190–192.
|
